Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib pharmacokinetics and CYP3A4/BMI study in early HER2-positive breast cancer
ChiCTR2400094664Phase 2Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of neratinib in breast cancer, sponsored by Huashan Hospital. Primary endpoint: Steady-state neratinib trough plasma concentration. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
neratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400094664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094664.